Cerium-doped Prussian blue biomimetic nanozyme as an amplified pyroptosis inhibitor mitigate Aβ oligomer-induced neurotoxicity in Alzheimer’s disease

Abstract Antioxidant enzyme therapy shows promise for treating Alzheimer’s disease (AD), but significant challenges remain in achieving effective blood–brain barrier (BBB) penetration and sustained therapeutic effects. We developed a novel neutrophil membrane (NM)-coated cerium-doped Prussian blue b...

Full description

Saved in:
Bibliographic Details
Main Authors: Jing Ma, Yu Tian, Chengzhong Du, Yang Zhu, Wen Huang, Chenyu Ding, Penghui Wei, Xuehan Yi, Zhangya Lin, Wenhua Fang
Format: Article
Language:English
Published: BMC 2025-03-01
Series:Journal of Nanobiotechnology
Subjects:
Online Access:https://doi.org/10.1186/s12951-025-03263-8
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850072237049118720
author Jing Ma
Yu Tian
Chengzhong Du
Yang Zhu
Wen Huang
Chenyu Ding
Penghui Wei
Xuehan Yi
Zhangya Lin
Wenhua Fang
author_facet Jing Ma
Yu Tian
Chengzhong Du
Yang Zhu
Wen Huang
Chenyu Ding
Penghui Wei
Xuehan Yi
Zhangya Lin
Wenhua Fang
author_sort Jing Ma
collection DOAJ
description Abstract Antioxidant enzyme therapy shows promise for treating Alzheimer’s disease (AD), but significant challenges remain in achieving effective blood–brain barrier (BBB) penetration and sustained therapeutic effects. We developed a novel neutrophil membrane (NM)-coated cerium-doped Prussian blue biomimetic nanozyme (NM@PB-Ce) that demonstrates outstanding enzymatic properties and targeted therapeutic efficacy. Extensive physicochemical characterization using transmission electron microscopy, X-ray photoelectron spectroscopy, and dynamic light scattering confirmed the successful synthesis of uniform nanoparticles (~ 142 nm) with preserved membrane protein functionality. In vitro studies utilizing SH-SY5Y neuroblastoma cells revealed that NM@PB-Ce effectively scavenged reactive oxygen species through multiple enzyme-mimetic activities (catalase, superoxide dismutase, and peroxidase). The nanozyme significantly suppressed NLRP3 inflammasome activation and subsequent pyroptosis, reducing inflammatory markers (IL-1β, IL-18) while attenuating Aβ aggregation. Using a sophisticated co-culture BBB model and real-time in vivo fluorescence imaging, we demonstrated NM@PB-Ce’s ability to traverse the BBB and accumulate specifically in AD-affected regions. In an Aβ1-42 oligomer-induced AD mouse model, systematic administration of NM@PB-Ce (320 μg/mL, 0.01 mL/g/day for 14 days) significantly improved cognitive performance across multiple behavioral paradigms, including the Morris water maze, Y-maze, and open field tests. Molecular and histological analyses revealed decreased neuroinflammation markers (GFAP, Iba-1) in the hippocampus, reduced levels of NLRP3, caspase-1, and phosphorylated tau (demonstrated by Western blot and ELISA), and enhanced dendritic spine density (visualized through Golgi staining). This comprehensive study establishes NM@PB-Ce as a promising therapeutic platform for AD treatment, providing both mechanistic insights into its mode of action and robust evidence of its therapeutic efficacy in targeting neuroinflammation and cognitive decline. Graphical Abstract
format Article
id doaj-art-44a05413cd334b6e88e90cd73639bac9
institution DOAJ
issn 1477-3155
language English
publishDate 2025-03-01
publisher BMC
record_format Article
series Journal of Nanobiotechnology
spelling doaj-art-44a05413cd334b6e88e90cd73639bac92025-08-20T02:47:07ZengBMCJournal of Nanobiotechnology1477-31552025-03-0123112210.1186/s12951-025-03263-8Cerium-doped Prussian blue biomimetic nanozyme as an amplified pyroptosis inhibitor mitigate Aβ oligomer-induced neurotoxicity in Alzheimer’s diseaseJing Ma0Yu Tian1Chengzhong Du2Yang Zhu3Wen Huang4Chenyu Ding5Penghui Wei6Xuehan Yi7Zhangya Lin8Wenhua Fang9Department of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital, Fujian Medical UniversityDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital, Fujian Medical UniversityDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital, Fujian Medical UniversityDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital, Fujian Medical UniversityDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital, Fujian Medical UniversityDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital, Fujian Medical UniversityDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital, Fujian Medical UniversityDepartment of Otolaryngology Head and Neck Surgery, Fujian Medical University Union HospitalDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital, Fujian Medical UniversityDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital, Fujian Medical UniversityAbstract Antioxidant enzyme therapy shows promise for treating Alzheimer’s disease (AD), but significant challenges remain in achieving effective blood–brain barrier (BBB) penetration and sustained therapeutic effects. We developed a novel neutrophil membrane (NM)-coated cerium-doped Prussian blue biomimetic nanozyme (NM@PB-Ce) that demonstrates outstanding enzymatic properties and targeted therapeutic efficacy. Extensive physicochemical characterization using transmission electron microscopy, X-ray photoelectron spectroscopy, and dynamic light scattering confirmed the successful synthesis of uniform nanoparticles (~ 142 nm) with preserved membrane protein functionality. In vitro studies utilizing SH-SY5Y neuroblastoma cells revealed that NM@PB-Ce effectively scavenged reactive oxygen species through multiple enzyme-mimetic activities (catalase, superoxide dismutase, and peroxidase). The nanozyme significantly suppressed NLRP3 inflammasome activation and subsequent pyroptosis, reducing inflammatory markers (IL-1β, IL-18) while attenuating Aβ aggregation. Using a sophisticated co-culture BBB model and real-time in vivo fluorescence imaging, we demonstrated NM@PB-Ce’s ability to traverse the BBB and accumulate specifically in AD-affected regions. In an Aβ1-42 oligomer-induced AD mouse model, systematic administration of NM@PB-Ce (320 μg/mL, 0.01 mL/g/day for 14 days) significantly improved cognitive performance across multiple behavioral paradigms, including the Morris water maze, Y-maze, and open field tests. Molecular and histological analyses revealed decreased neuroinflammation markers (GFAP, Iba-1) in the hippocampus, reduced levels of NLRP3, caspase-1, and phosphorylated tau (demonstrated by Western blot and ELISA), and enhanced dendritic spine density (visualized through Golgi staining). This comprehensive study establishes NM@PB-Ce as a promising therapeutic platform for AD treatment, providing both mechanistic insights into its mode of action and robust evidence of its therapeutic efficacy in targeting neuroinflammation and cognitive decline. Graphical Abstracthttps://doi.org/10.1186/s12951-025-03263-8NanozymeAlzheimer’s diseasePyroptosisReactive oxygen speciesNeuroinflammation
spellingShingle Jing Ma
Yu Tian
Chengzhong Du
Yang Zhu
Wen Huang
Chenyu Ding
Penghui Wei
Xuehan Yi
Zhangya Lin
Wenhua Fang
Cerium-doped Prussian blue biomimetic nanozyme as an amplified pyroptosis inhibitor mitigate Aβ oligomer-induced neurotoxicity in Alzheimer’s disease
Journal of Nanobiotechnology
Nanozyme
Alzheimer’s disease
Pyroptosis
Reactive oxygen species
Neuroinflammation
title Cerium-doped Prussian blue biomimetic nanozyme as an amplified pyroptosis inhibitor mitigate Aβ oligomer-induced neurotoxicity in Alzheimer’s disease
title_full Cerium-doped Prussian blue biomimetic nanozyme as an amplified pyroptosis inhibitor mitigate Aβ oligomer-induced neurotoxicity in Alzheimer’s disease
title_fullStr Cerium-doped Prussian blue biomimetic nanozyme as an amplified pyroptosis inhibitor mitigate Aβ oligomer-induced neurotoxicity in Alzheimer’s disease
title_full_unstemmed Cerium-doped Prussian blue biomimetic nanozyme as an amplified pyroptosis inhibitor mitigate Aβ oligomer-induced neurotoxicity in Alzheimer’s disease
title_short Cerium-doped Prussian blue biomimetic nanozyme as an amplified pyroptosis inhibitor mitigate Aβ oligomer-induced neurotoxicity in Alzheimer’s disease
title_sort cerium doped prussian blue biomimetic nanozyme as an amplified pyroptosis inhibitor mitigate aβ oligomer induced neurotoxicity in alzheimer s disease
topic Nanozyme
Alzheimer’s disease
Pyroptosis
Reactive oxygen species
Neuroinflammation
url https://doi.org/10.1186/s12951-025-03263-8
work_keys_str_mv AT jingma ceriumdopedprussianbluebiomimeticnanozymeasanamplifiedpyroptosisinhibitormitigateaboligomerinducedneurotoxicityinalzheimersdisease
AT yutian ceriumdopedprussianbluebiomimeticnanozymeasanamplifiedpyroptosisinhibitormitigateaboligomerinducedneurotoxicityinalzheimersdisease
AT chengzhongdu ceriumdopedprussianbluebiomimeticnanozymeasanamplifiedpyroptosisinhibitormitigateaboligomerinducedneurotoxicityinalzheimersdisease
AT yangzhu ceriumdopedprussianbluebiomimeticnanozymeasanamplifiedpyroptosisinhibitormitigateaboligomerinducedneurotoxicityinalzheimersdisease
AT wenhuang ceriumdopedprussianbluebiomimeticnanozymeasanamplifiedpyroptosisinhibitormitigateaboligomerinducedneurotoxicityinalzheimersdisease
AT chenyuding ceriumdopedprussianbluebiomimeticnanozymeasanamplifiedpyroptosisinhibitormitigateaboligomerinducedneurotoxicityinalzheimersdisease
AT penghuiwei ceriumdopedprussianbluebiomimeticnanozymeasanamplifiedpyroptosisinhibitormitigateaboligomerinducedneurotoxicityinalzheimersdisease
AT xuehanyi ceriumdopedprussianbluebiomimeticnanozymeasanamplifiedpyroptosisinhibitormitigateaboligomerinducedneurotoxicityinalzheimersdisease
AT zhangyalin ceriumdopedprussianbluebiomimeticnanozymeasanamplifiedpyroptosisinhibitormitigateaboligomerinducedneurotoxicityinalzheimersdisease
AT wenhuafang ceriumdopedprussianbluebiomimeticnanozymeasanamplifiedpyroptosisinhibitormitigateaboligomerinducedneurotoxicityinalzheimersdisease